Your browser doesn't support javascript.
loading
Therapeutic efficacy of IL-2-loaded hydrogels in a mouse tumor model.
De Groot, Cornelis J; Cadée, Jenny A; Koten, Jan-Willem; Hennink, Wim E; Den Otter, Willem.
Afiliação
  • De Groot CJ; Faculty of Veterinary Medicine, Department of Cell Biology and Histology, Utrecht University, Utrecht, The Netherlands.
Int J Cancer ; 98(1): 134-40, 2002 Mar 01.
Article em En | MEDLINE | ID: mdl-11857397
Interleukin-2 (IL-2) is a highly effective anticancer drug if it is applied locally for 5 consecutive days. In most cases this requires 5 invasive treatments, which is not usually acceptable for either the patient or the clinician. For this reason we have developed dextran-based hydrogels from which the required amount of encapsulated IL-2 (1-4 x 10(6) IU of IL-2) is gradually released during 5-10 days. Initially IL-2-containing macroscopic cylinder-shaped gels (implants), and later IL-2-containing injectable microspheres, were developed. These preparations were characterized in vitro, and the therapeutic activity was tested in DBA/2 mice with SL2 lymphosarcoma. The therapy was given to mice with a large and extensively metastasized tumor load (at least 5% of the body weight). If 1-4 x 10(6) IU of IL-2 was slowly released from the hydrogels over a period of 5-10 days, the therapeutic effects were very good and comparable to the effects of free IL-2 injections for 5 consecutive days. In conclusion, dextran-based hydrogels are promising systems for the controlled release of IL-2.
Assuntos
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Interleucina-2 / Neoplasias Experimentais Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Int J Cancer Ano de publicação: 2002 Tipo de documento: Article País de afiliação: Holanda País de publicação: Estados Unidos
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Interleucina-2 / Neoplasias Experimentais Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Int J Cancer Ano de publicação: 2002 Tipo de documento: Article País de afiliação: Holanda País de publicação: Estados Unidos